New pill shows promise for lung cancer patients with Hard-to-Treat mutation
NCT ID NCT02442349
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a daily pill called AZD9291 in 171 people from Asia Pacific with advanced lung cancer that has a specific genetic change (T790M mutation). The goal was to see if the drug could shrink tumors and control the disease after other treatments stopped working. Researchers measured how many patients had their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD9291 (osimertinib) - a targeted cancer drug taken as a daily tablet
What this could lead to
If successful, this could provide a new treatment option for lung cancer patients with a specific genetic mutation (T790M) whose disease has worsened after other therapies.
What could go wrong
This is a phase 2 trial with a small number of patients (171) and no comparison group, so results may not apply to everyone. The drug may not work for all patients and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Kogarah, 2217, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Woolloongabba, 4102, Australia
-
Research Site
Beijing, 100021, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100730, China
-
Research Site
Changchun, 130000, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400038, China
-
Research Site
Chongqing, 400042, China
-
Research Site
Fuzhou, 350014, China
-
Research Site
Haikou, 570311, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hangzhou, 310006, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150049, China
-
Research Site
Jinan, 250117, China
-
Research Site
Nanjing, 210009, China
-
Research Site
Shanghai, 200030, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, CN-200433, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Xi'an, 710032, China
-
Research Site
Xi'an, 710038, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 6351, South Korea